Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

Authors

  • Anthony D. Yang M.D.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Todd W. Bauer M.D.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • E. Ramsay Camp M.D.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Ray Somcio B.S.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Wenbiao Liu Ph.D.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Fan Fan B.S.,

    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Lee M. Ellis M.D.

    Corresponding author
    1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    2. Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Surgical Oncology, Unit 4444, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402
    Search for more papers by this author
    • Fax: (713) 792-4689


Abstract

It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens. Cancer 2005. © 2005 American Cancer Society.

Ancillary